Literature DB >> 3489089

Suppression of immune function in growth hormone-deficient children during treatment with human growth hormone.

R Rapaport, J Oleske, H Ahdieh, S Solomon, C Delfaus, T Denny.   

Abstract

Inasmuch as growth hormone is known to interact with the immune system, we studied immune functions including immunoglobulins, cell surface markers, mitogen responses, and polymorphonuclear cell function in eight children with growth hormone deficiency, ages 1 to 17 years, before and during treatment with human growth hormone for 12 to 16 months. Before treatment immune functions were normal in all children. Treatment with human growth hormone did not significantly affect serum immunoglobulins, polymorphonuclear cell function, or percent T cells. However, percent B cells decreased to subnormal levels in seven of seven patients. T helper/suppressor ratios decreased in all patients, to subnormal values in seven of eight patients; and mitogen responses decreased to below normal in all. The decline of percent B cells was transient in all patients, of T helper/suppressor ratios in seven of eight, and mitogen responses in five of eight patients. In vitro incubation of lymphocytes with growth hormone resulted in no changes in cell surface markers or mitogen responses. Although the depression of immune functions resulted in no increased rate of infections during the observation period, we do not know the possible effects of prolonged treatment and therefore caution against the indiscriminate use of human growth hormone. The effects of biosynthetically obtained growth hormone on immune function remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489089     DOI: 10.1016/s0022-3476(86)80113-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  7 in total

Review 1.  Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways.

Authors:  Dennis D Taub; William J Murphy; Dan L Longo
Journal:  Curr Opin Pharmacol       Date:  2010-06-04       Impact factor: 5.547

2.  Localization of growth hormone receptor messenger RNA in human tissues.

Authors:  H C Mertani; M C Delehaye-Zervas; J F Martini; M C Postel-Vinay; G Morel
Journal:  Endocrine       Date:  1995-02       Impact factor: 3.633

3.  Lymphocyte subset pattern in acromegaly.

Authors:  A Colao; D Ferone; P Marzullo; N Panza; R Pivonello; F Orio; G Grande; N Bevilacqua; G Lombardi
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

4.  Thymulin, zinc and insulin-like growth factor-I (IGF-I) activity before and during recombinant growth hormone (rec-GH) therapy in children and adults with GH deficiency.

Authors:  E Mocchegiani; A Sartorio; L Santarelli; S Ferrero; N Fabris
Journal:  J Endocrinol Invest       Date:  1996-10       Impact factor: 4.256

5.  Growth hormone alters lymphocyte sub-populations and antibody production in dwarf rats in vivo.

Authors:  A Schurmann; G S Spencer; C J Berry
Journal:  Experientia       Date:  1995-08-16

6.  Antibody deficiency and isolated growth hormone deficiency in a girl with Mulibrey nanism.

Authors:  A Haraldsson; C J van der Burgt; C M Weemaes; B Otten; J A Bakkeren; G B Stoelinga
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

7.  Organ- and non-organ-specific auto-antibodies in children with hypopituitarism on growth hormone therapy.

Authors:  M Maghnie; R Lorini; L Vitali; N Mastricci; A M Carrà; F Severi
Journal:  Eur J Pediatr       Date:  1995-06       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.